Daniel Li
Impact in
Papers in
- Co-authors
- Richard R. Furman (5 shared papers)Steven Coutré (4 shared papers)John C. Byrd (3 shared papers)David G. Maloney (6 shared papers)Stanley R. Riddell (6 shared papers)Cameron J. Turtle (6 shared papers)Jennifer R. Brown (3 shared papers)Laïla‐Aïcha Hanafi (4 shared papers)
- Journals
- Journal of Clinical Oncology (10 papers)Blood (9 papers)Lara D. Veeken (2 papers)Mucosal Immunology (2 papers)The Laryngoscope (2 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Daniel Li
60 papers receiving 2.4k citations
Daniel Li's Hit Papers
Peers
Comparison fields: 5 of 116
- Genetics 831
- Oncology 991
- Pathology and Forensic Medicine 552
- Hematology 252
- Immunology 436
Countries citing papers authored by Daniel Li
This map shows the geographic impact of Daniel Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Li more than expected).
Fields of papers citing papers by Daniel Li
This network shows the impact of papers produced by Daniel Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Li. The network helps show where Daniel Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 65 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib Hit paper breakdown → | 2017 | 506 |
| 2 | Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia Hit paper breakdown → | 2014 | 479 |
| 3 | 2019 | 251 | |
| 4 | 2015 | 234 | |
| 5 | 2020 | 92 | |
| 6 | 2013 | 78 | |
| 7 | 2013 | 62 | |
| 8 | 2015 | 57 | |
| 9 | 2016 | 54 | |
| 10 | 2013 | 39 | |
| 11 | 1995 | 38 | |
| 12 | 2013 | 31 | |
| 13 | 2013 | 30 | |
| 14 | 2015 | 30 | |
| 15 | 2019 | 27 | |
| 16 | 2017 | 25 | |
| 17 | 2021 | 23 | |
| 18 | 2016 | 23 | |
| 19 | 2019 | 22 | |
| 20 | 2020 | 20 |
About Daniel Li
Daniel Li is a scholar working on Oncology, Genetics, Pulmonary and Respiratory Medicine, Immunology and Public Health, Environmental and Occupational Health, having authored 65 papers that have together received 2.4k indexed citations. Recurring topics across this work include CAR-T cell therapy research (16 papers), Chronic Lymphocytic Leukemia Research (11 papers), Acute Lymphoblastic Leukemia research (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Systemic Lupus Erythematosus Research (4 papers), Immunodeficiency and Autoimmune Disorders (4 papers), Infection Control and Ventilation (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Genetics (831 citations), Oncology (991 citations), Pathology and Forensic Medicine (552 citations), Hematology (252 citations) and Immunology (436 citations). Daniel Li has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Richard R. Furman, Steven Coutré, John C. Byrd, David G. Maloney, Stanley R. Riddell, Cameron J. Turtle, Jennifer R. Brown, Laïla‐Aïcha Hanafi, Shelly Heimfeld and Sindhu Cherian. Their work appears in journals such as Journal of Clinical Oncology, Blood, Lara D. Veeken, Mucosal Immunology and The Laryngoscope.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.